




Adding Health to Life...

COMPANY
PRESENTATION

Member of EastPharma 



Adding Health to Life...

For a healthier future, we strive to provide accessible, innovative and quality products to the service of patients.

We care about being a respected and preferred brand on a global scale with our reliable products.



Areas of Interest




Q DEVA at a Glance...


- DEVA, a long-standing pharmaceutical manufacturer in Turkey since 1958
- In 2019, it was the second company in the sector with a 6.4% market share.
- Approximately 600 products in 13 therapeutic areas.
- 3 production facilities in Çerkezköy and Kartepe.
- With an R&D team of approximately 190 expert scientists, it is working to provide accessible and innovative products to the service all over the world.
- In 2019, DEVA allocated 6% of its turnover to R & D.
- It continues its activities with approximately 2400 employees.
- Production facilities have EU GMP and US FDA approvals.



Q DEVA at a Glance...



DEVA at a Glance...



Strong Production Capabilities

Total Land Area

216.409 sqm

Covered Production Area

90.204 sqm

Annual Production Capacity

578 Million Units

**Cerkezkoy
Manufacturing Site**
(Tekirdag)



Headquarter
(Istanbul)



**Cerkezkoy
Manufacturing
Site**
(Tekirdag)



**Cerkezkoy
Manufacturing Site
Logistics Center**
(Tekirdag)



**Kartepe
Manufacturing
Site**
(Izmit)

Cerkezkoy I Manufacturing Site



Solid Manufacturing Unit

- ❖ Dry powder suspensions
- ❖ Tablets
- ❖ Capsules

Liquid / Semi Solid Manufacturing Unit

- ❖ Creams, pomades & gels
- ❖ Eye pomads
- ❖ Suppozituar
- ❖ Drops

Cephalosporin Manufacturing Unit

- ❖ Sterile powder vial
- ❖ Dry suspensions
- ❖ Tablets
- ❖ Capsules

Penicilin Manufacturing Unit

- ❖ Sterile powder vial
- ❖ Dry suspensions
- ❖ Tablets

Hormone Products Manufacturing Unit (Non sterile)

- ❖ Tablets
- ❖ Coated Tablets
- ❖ Creams - Gels - Pomades
- ❖ Lotion & packaging

Hormone Products Manufacturing Unit (Sterile)

- ❖ Ampoules
- ❖ Vial
- ❖ Drops

Inhaled Products

- ❖ MDI (Metered Dose Inhaler)
- ❖ DPI (Dry powder Inhaler)
- ❖ Nebule

Sterile Liquid Vial and Soft Gel Capsule Products

- ❖ Sterile Liquid Vial
- ❖ Sterile Liquid Ampoules
- ❖ Soft Gel Capsule



Cerkezkoy II Manufacturing Site



API Production Units

- ❖ Non-betalactam
- ❖ Betalactam (sterile & non-sterile)
- ❖ Oncolytic

Human Finished Dosage Forms Production Units

- ❖ Solid Oncolytics (tablets & capsules)
- ❖ Sterile Liquid Oncolytics (liquid & lyophilized vials)

Animal Health Products Production Units

- ❖ Solids (tablets & powders)
- ❖ Sterile suspensions and pomade



Kartepe Manufacturing Site




Empty& filled ampoule production: 1ml - 20ml

Sterile vial & lyophilisation production: 2ml - 200ml

SVP production with BFS technology

- ❖ Unit dose: 0.5ml - 2.5ml (LDPE)
- ❖ Multidose & Inj: 2.5ml - 10 ml (LDP)

Cologne production



DEVA Logistics Center



Turkey's largest pharmaceutical logistics center

Total Land Area

58.000 sqm

Closed Area

30.000 sqm

Pallet Area

26.000 sqm

Pallet Capacity

32.000



Broad Range of Products

Non-sterile

- ❖ Tablets
- ❖ Coated Tablets
- ❖ Enteric – Coated Tablets
- ❖ Capsules
- ❖ Micropellet Capsules
- ❖ Sugar Coated Pills
- ❖ Syrups
- ❖ Suspensions
- ❖ Creams
- ❖ Pomades
- ❖ Ointments
- ❖ Drops
- ❖ Sprays
- ❖ Gels
- ❖ Suppositories
- ❖ MDI (Metered Dose Inhaler)
- ❖ DPI (Dry Powder Inhaler)

Sterile

- ❖ Ampoules
- ❖ Vials
- ❖ Lyophilisation
- ❖ BFS SVP (Eye drop nebul)
- ❖ Sterile Raw Material
- ❖ Sterile Animal Health






DEVA in Turkey...

DEVA ranks **2nd** among the pharmaceutical companies

Year-end Marketing Shares Report (unit-base)





Growing in International Markets

- 2014 - First registration application to US FDA.
- 2014 - License approvals in 19 countries including Germany, Switzerland, Netherlands, Australia and New Zealand.
- 2015 - The number of our licenses reached 350 in 31 countries.
- 2016 - Kartepe Facility received US FDA approval.
- 2016 - DEVATIS started operations in Germany.
- 2017 - Çerkezköy II Facility received US FDA approval.
- 2017 - First export to USA.
- 2018 - Devatis approved by Swissmedic in Switzerland. Devatis accelerated its activities in USA.
- 2019 - First pharmaceutical export to Switzerland begins.






Growing in International Markets

Over 700 license approvals in more than 60 countries.

Exports of pharmaceuticals and pharmaceutical raw materials to more than 50 countries.





Turkey is a member of PIC/S

Turkey, in 2018 the Pharmaceutical Inspection Co-operation Scheme ("PIC/S") has been accepted into membership. PIC/S is the most respected and valid institution recognized in this field as a union established by the drug licensing authorities in the world.

Turkey's PIC/S made by TITCK along with being a member of the audit will be recognized all over the world. The process for pharmaceutical manufacturers and exporters in Turkey is expected to increase further simplification and pharmaceutical exports.

PIC/S member countries: Switzerland, USA, UK, Ireland, Germany, Canada, Japan, Australia





Key Therapeutic Areas

We are working and producing for a healthier future with about 600 products in 13 therapeutic areas.





Vetas operates in Animal Health

- Since 1973 Vetas rooted in Turkey operating in the veterinary field and a local manufacturer.
- There are 90 products and 140 product forms in 7 different therapeutic areas.
- The products are manufactured in GMP certified DEVA production facilities located in Cerkezkoy and Kartepe.
- Vetas, which is one of the top 3 companies in the animal health medicine market, ranks first among the domestic companies.
- With its R&D team for animal health, it provides accessible, innovative and high-quality products to veterinarians.
- With the Vetakademi Campus training program, which started in 2014, Vetas reaches nearly 1000 veterinarians throughout the year.
- Its activities continues with 40 staff, most of whom are veterinarians.





We are Proud of our Awards

In 2015, DEVA was selected as the best R&D company in the pharmaceutical industry in the 4th Private Sector R&D Centers Summit organized by the Ministry of Science Industry and Technology.

DEVA was awarded 3 times with 3 different products by Golden Mortar, one of the most prestigious awards of the pharmaceutical industry.



4th Special Sector
R&D CENTERS SUMMIT
THE BEST R&D



**GOLDEN
MORTAR
THE BEST
R&D
AWARD**

VERTICAL INTEGRATION




IMATIS
imatinib

Benipin

rivetime lenalidomide

Gilomid
fingolimod



Rising Star of the Industry **DEVARGE**

We are proud to be the local pharmaceutical company that allocates the highest share of R&D from its total turnover with **6%**.

(Turkishtime, R&D Research, 2019)



We are Socially Responsible...

In the 100th year of the Dardanelles War, we reprinted *Acı İlaç* discussing the health aspect of the war and narrating the sacrificed lives due to incurable illnesses and impossibilities



We have started a scholarship program to support successful medical and pharmacy students.

We are Socially Responsible...

DEVA officially supports Turk Kizilay.



Our Power is Our Employees...

We, as DEVA, are conscious of the fact that our greatest advantage in the competition environment is our self-sacrificing employees with high competency.

We treasure our employees and believe that this power will move us to our goals in a short span of time in becoming a global corporation.





SINCE
1958

" This presentation has been prepared by DEVA Holding A.Ş. as an information document for healthcare professionals only within the scope of the Regulation on Promotion Activities of Human Medicinal Products and other related legal regulations. It can not be reproduced, distributed or shared in any way. DEVA Holding A.Ş. is responsible for any shares and legal responsibilities that may arise outside of the purpose stated herein without the permission and approval of DEVA Holding A.Ş. will not be responsible. "



www.deva.com.tr/en

DEVA Holding

EastPharma 

